Moreover, the union of ginsenoside Rg3 and paclitaxel elicited a more pronounced reduction in Bcl-2 protein expression, accompanied by an augmentation in Bax and Caspase-3 protein expression within breast cancer cells, thus fortifying the tumor-suppressive potential beyond that of paclitaxel monotherapy (Yuan et al., 2017). This evidence concerns the gene BCL2 and breast cancer.